Sökning: WFRF:(Butler Oisin) >
Poor outcome of pat...
-
Hjalmarsson, Clara,1969Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
(författare)
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy : a registry-based study
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-09
-
Sage Publications,2020
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-176169
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-176169URI
-
https://doi.org/10.1177/2045894020958557DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170926URI
-
https://lup.lub.lu.se/record/09e6f9e8-89fc-46a0-b882-1532a79eb246URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:144861932URI
-
https://gup.ub.gu.se/publication/297361URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Swedish Association of Local Authorities and Regions; Merck & Co., Inc. Kenilworth NJ, USA; Bayer AG, Berlin, Germany
-
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect. This study aimed to investigate the clinical course of pulmonary arterial hypertension patients not at treatment goal after at least 90 days of treatment with phosphodiesterase-5 inhibitors, alone or in combination with other pulmonary arterial hypertension therapies. The study included 106 incident patients from the Swedish Pulmonary Arterial Hypertension Registry, treated with phosphodiesterase-5 inhibitors for >= 90 days, who were not at a pre-specified treatment goal, i.e. in World Health Organisation functional class III, with 6-min walking distance 165-440 m, and N-terminal prohormone of brain natriuretic peptide >300 ng/L. Changes in World Health Organisation functional class, 6-min walking distance, N-terminal prohormone of brain natriuretic peptide, and risk group between index and follow-up were assessed. Of patients with complete follow-up data, (n = 53) 77% were on combination therapy and risk assessment yielded 98% at intermediate risk at index. At follow-up, 11 patients transitioned from World Health Organisation functional class III to World Health Organisation functional class II, the median (Q1; Q3) change in 6-min walking distance was 6 (-30; 42) meters and in N-terminal prohormone of brain natriuretic peptide 47 (-410; 603) ng/L, while 89% remained at an intermediate risk. Of those without complete follow-up data, 11 patients died and 2 underwent lung transplantation. In conclusion, pulmonary arterial hypertension patients treated with phosphodiesterase-5 inhibitors, as single or combination therapy and not achieving the pre-specified treatment goals after >= 90 days have an unfavourable clinical course.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Butler, OisinBayer AG, Germany,Bayer Pharma AG
(författare)
-
Hesselstrand, RogerLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Forskargruppen för systemisk skleros, Lund,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Lund Systemic Sclerosis Research Group,Skåne University Hospital(Swepub:lu)reum-rhe
(författare)
-
Holl, KatsiarynaBayer AG, Germany,Bayer Pharma AG
(författare)
-
Jansson, KjellLinköping University,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Fysiologiska kliniken US(Swepub:liu)kjeja02
(författare)
-
Klok, RogierMerck Sharp And Dohme Corp., US
(författare)
-
Rådegran, GöranLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Lund Hemodynamic Lab,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-grd
(författare)
-
Söderberg, StefanUmeå University,Umeå universitet,Kardiologi,Avdelningen för medicin,Heart Centre, Umeå University,Umea Univ, Sweden(Swepub:umu)stso0001
(författare)
-
Kjellström, BarbroKarolinska Institutet,Lund University,Lunds universitet,Klinisk fysiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Clinical Physiology (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)ba8516kj
(författare)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Pulmonary Circulation: Sage Publications10:32045-89322045-8940
Internetlänk
Hitta via bibliotek
Till lärosätets databas